title: Long-term quality of life in patients with rectal cancer treated with preoperative (chemo)-radiotherapy within a randomized trial.
abstract: OBJECTIVE
  Few studies have evaluated the quality of life (QoL) of patients with rectal cancer. This report describes the quality of life of French patients who entered the 22921 EORTC trial that investigated the role and place of chemotherapy (CT) added to preoperative radiotherapy (preop-RT).
  
  
  METHODS
  Patients without recurrences were evaluated with EORTC QLQ-C30 and QLQ-CR38 questionnaires, after a median time of 4.6 years from randomisation.
  
  
  RESULTS
  All the scores of QLQ-C30 functions were high, from 78 up to 88, with those of global health quality of life scale (GHQL) status being 73. The mean scores of symptoms were low except for diarrhoea. For QLQ-CR38, the mean scores for "body image" and "future perspective" were high at 79.6 and 69.7 respectively. The scores for "sexual functioning" and "enjoyment" were low. Men had more sexual problems than females (62.5 vs 25 mean scores respectively). Chemotherapy was associated with more diarrhoea complaints, lower "role", lower "social functioning" and lower global health quality of life scale.
  
  
  CONCLUSIONS
  The overall quality of life of patients with rectal cancer is quite good 4.6 years after the beginning preoperative treatments. However, adding chemotherapy to preoperative radiotherapy has a negative effect on diarrhoea complaints and some quality of life dimensions.
authors.affiliation: EA3181, Besançon University Hospital, University of Franche-Comté, 2 place Saint-Jacques, 25030 Besançon cedex, France.
authors.forename: M
authors.initials: M
authors.lastname: Tiv
authors.forename: M
authors.initials: M
authors.lastname: Puyraveau
authors.forename: L
authors.initials: L
authors.lastname: Mineur
authors.forename: G
authors.initials: G
authors.lastname: Calais
authors.forename: P
authors.initials: P
authors.lastname: Maingon
authors.forename: E
authors.initials: E
authors.lastname: Bardet
authors.forename: M
authors.initials: M
authors.lastname: Mercier
authors.forename: J-F
authors.initials: JF
authors.lastname: Bosset
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000523:psychology* / Q000532:radiotherapy / Q000601:surgery; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001828:Body Image; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects* / Q000523:psychology; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D003967:Diarrhea / Q000209:etiology / Q000523:psychology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007398:Interpersonal Relations; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000009:adverse effects* / Q000523:psychology; D011788:Quality of Life; D011832:Radiation Injuries / Q000209:etiology / Q000523:psychology; D011878:Radiotherapy / Q000009:adverse effects; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000523:psychology* / Q000532:radiotherapy / Q000601:surgery; D012735:Sexual Dysfunction, Physiological / Q000209:etiology / Q000523:psychology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents